| Prevention of prescription opioid misuse and projected overdose deaths in the United States Q Chen, MR Larochelle, DT Weaver, AP Lietz, PP Mueller, S Mercaldo, ... JAMA network open 2 (2), e187621-e187621, 2019 | 326 | 2019 |
| Economic burden of chronic lymphocytic leukemia in the era of oral targeted therapies in the United States Q Chen, N Jain, T Ayer, WG Wierda, CR Flowers, SM O’Brien, MJ Keating, ... Journal of Clinical Oncology 35 (2), 166-174, 2017 | 201 | 2017 |
| First-and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: a United States–based cost-effectiveness analysis DA Goldstein, Q Chen, T Ayer, DH Howard, J Lipscomb, BF El-Rayes, ... Journal of Clinical Oncology 33 (10), 1112-1118, 2015 | 171 | 2015 |
| Cost-effectiveness analysis of regorafenib for metastatic colorectal cancer DA Goldstein, BB Ahmad, Q Chen, T Ayer, DH Howard, J Lipscomb, ... Journal of Clinical Oncology 33 (32), 3727-3732, 2015 | 116 | 2015 |
| Cost-Effectiveness of Immune Checkpoint Inhibition in BRAF Wild-Type Advanced Melanoma CG Kohn, SB Zeichner, Q Chen, AJ Montero, DA Goldstein, CR Flowers Journal of Clinical Oncology 35 (11), 1194-1202, 2017 | 113 | 2017 |
| Cost-effectiveness of hepatitis C treatment using generic direct-acting antivirals available in India R Aggarwal, Q Chen, A Goel, N Seguy, R Pendse, T Ayer, J Chhatwal PloS one 12 (5), e0176503, 2017 | 105 | 2017 |
| Should we treat acute hepatitis C? A decision and cost‐effectiveness analysis ED Bethea, Q Chen, C Hur, RT Chung, J Chhatwal Hepatology 67 (3), 837-846, 2018 | 78 | 2018 |
| The impact of direct‐acting anti‐virals on the hepatitis C care cascade: identifying progress and gaps towards hepatitis C elimination in the United States J Chhatwal, Q Chen, ED Bethea, C Hur, AC Spaulding, F Kanwal Alimentary pharmacology & therapeutics 50 (1), 66-74, 2019 | 61 | 2019 |
| Artificial neural networks in mammography interpretation and diagnostic decision making T Ayer, Q Chen, ES Burnside Computational and mathematical methods in medicine 2013 (1), 832509, 2013 | 61 | 2013 |
| Buying time for an effective epidemic response: the impact of a public holiday for outbreak control on COVID-19 epidemic spread S Chen, Q Chen, W Yang, L Xue, Y Liu, J Yang, C Wang, ... Engineering 6 (10), 1108-1114, 2020 | 51 | 2020 |
| Cost effectiveness analysis of pharmacokinetically-guided 5-fluorouracil in FOLFOX chemotherapy for metastatic colorectal cancer DA Goldstein, Q Chen, T Ayer, DH Howard, J Lipscomb, RD Harvey, ... Clinical colorectal cancer 13 (4), 219-225, 2014 | 51 | 2014 |
| Changes in hepatitis C burden and treatment trends in Europe during the era of direct-acting antivirals: a modelling study Q Chen, T Ayer, E Bethea, F Kanwal, X Wang, M Roberts, Y Zhuo, ... BMJ open 9 (6), e026726, 2019 | 49 | 2019 |
| Necitumumab in metastatic squamous cell lung cancer: establishing a value-based cost DA Goldstein, Q Chen, T Ayer, DH Howard, J Lipscomb, SS Ramalingam, ... JAMA oncology 1 (9), 1293-1300, 2015 | 45 | 2015 |
| Comparing the cost-effectiveness of rituximab maintenance and radioimmunotherapy consolidation versus observation following first-line therapy in patients with follicular lymphoma Q Chen, T Ayer, LJ Nastoupil, AC Rose, CR Flowers Value in Health 18 (2), 189-197, 2015 | 45 | 2015 |
| Cost‐effectiveness of generic pan‐genotypic sofosbuvir/velpatasvir versus genotype‐dependent direct‐acting antivirals for hepatitis C treatment A Goel, Q Chen, J Chhatwal, R Aggarwal Journal of gastroenterology and hepatology 33 (12), 2029-2036, 2018 | 43 | 2018 |
| Exploring the potential cost-effectiveness of precision medicine treatment strategies for diffuse large B-cell lymphoma Q Chen, AD Staton, T Ayer, DA Goldstein, JL Koff, CR Flowers Leukemia & lymphoma 59 (7), 1700-1709, 2018 | 42 | 2018 |
| Bevacizumab for metastatic colorectal cancer: a global cost‐effectiveness analysis DA Goldstein, Q Chen, T Ayer, KKW Chan, K Virik, A Hammerman, ... The Oncologist 22 (6), 694-699, 2017 | 42 | 2017 |
| Assessment of the feasibility and cost of hepatitis C elimination in Pakistan J Chhatwal, Q Chen, X Wang, T Ayer, Y Zhuo, NZ Janjua, F Kanwal JAMA network open 2 (5), e193613-e193613, 2019 | 39 | 2019 |
| Optimal M-Switch Surveillance Policies for Liver Cancer in a Hepatitis C–Infected Population Q Chen, T Ayer, J Chhatwal Operations Research 66 (3), 673-696, 2018 | 39 | 2018 |
| Prevalence and economic burden of chronic lymphocytic leukemia (CLL) in the era of oral targeted therapies N Jain, Q Chen, T Ayer, SM O'Brien, M Keating, W Wierda, HM Kantarjian, ... Blood 126 (23), 871, 2015 | 37 | 2015 |
